These findings reveal the pivotal role of ASPM in drug resistance in lung cancer cells, suggesting that inhibition of the ASPM gene is an important therapeutic strategy for overcoming EGFR-TKI resistance. This evidence concerns the gene EGFR and lung carcinoma.